While the dollar amount is not large relative to market cap, the fact that both the CFO and CMO are selling shares simultaneously raises caution. Traders should monitor for any upcoming earnings releases or clinical trial updates that may have prompted this activity. The non-cash grants are routine and not economically significant.
Price Chart
Executive Summary
Multiple executives at Ultragenyx Pharmaceutical, including the CFO and Chief Medical Officer, conducted open-market share sales totaling over $317,000 in the past week, while also receiving non-cash stock awards. The selling activity is concentrated among C-suite insiders and represents a modest but notable cluster.
Key Financial Metrics
Key Facts
- CFO Howard Horn sold 6,925 shares for $157,236 in open-market transactions.
- Chief Medical Officer Eric Crombez sold 7,029 shares for $160,261 in open-market transactions.
- Dennis Karl Huang (executive) had 999 shares withheld for taxes, valued at $23,367.
- All three insiders also received stock awards totaling 28,923 shares (non-cash, $0 value).
- Total open-market sales by insiders: $317,497 over 3 days.
- Sales represent approximately 0.014% of Ultragenyx's $2.2B market cap.
Financial Impact
$317,497 in net open-market insider selling over 7 days
Risk Factors
- Insider selling by top executives can signal lack of confidence in near-term prospects.
- Potential for negative market sentiment despite small absolute size of transactions.
- Risk of misinterpretation due to conflation of non-cash award events with actual selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-RARE-1772581860515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $14.85 $15.22 | ▼ −2.49% | ▼ −3.68% | $15.22 (−2.49%) |
Sep 1, 2026 4w ago | Press Release | $26.53 $15.03 | ▼ −43.35% | ▼ −43.02% | $15.22 (−42.63%) |
Aug 11, 2026 7w ago | 8-K | $26.80 $14.31 | ▼ −46.60% | ▼ −45.55% | $15.22 (−43.21%) |
Aug 4, 2026 8w ago | 8-K | $24.93 $26.53 | ▲ +6.42% | ▲ +7.02% | $15.22 (−38.95%) |
Aug 4, 2026 8w ago | Insider Cluster | $25.81 $25.81 | · 0.00% | ▲ +1.24% | $15.22 (−41.03%) |
Jun 15, 2026 15w ago | Insider Cluster | $24.85 $32.03 | ▲ +28.89% | ▲ +28.69% | $15.22 (−38.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.98 $34.61 | ▲ +44.33% | ▲ +42.44% | $15.22 (−36.53%) |
May 5, 2026 21w ago | Press Release | $25.93 $22.41 | ▲ +13.57% | ▲ +16.36% | $15.22 (+41.30%) |
May 1, 2026 22w ago | Insider Cluster | $24.77 $22.85 | ▼ −7.75% | ▼ −13.04% | $15.22 (−38.55%) |
Apr 2, 2026 26w ago | 8-K | $22.45 $24.69 | ▲ +9.98% | ▲ +0.10% | $15.22 (−32.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access